Bioyitech Showcases Advancements in Functional Probiotic R&D at the 2025 International Conference on Functional Medicine
From November 13th to 15th, the 7th International Conference on Functional Medicine convened in Beijing. This significant event brought together leading global experts, clinicians, and industry representatives in the field of functional medicine to discuss the latest progress in disease prevention, health management, and industrial development. As a pioneer in China's functional probiotic sector, Bioyitech was invited to participate and deliver a keynote presentation, highlighting the company's innovative achievements in functional Probiotics.
Functional Probiotics Gain Attention for Metabolic Disease Prevention and Management
During the conference's "International Forum on Innovative Integration of Chronic Disease Management," Dr. Xu Xianrui, Vice President of R&D at Bioyitech, delivered a presentation titled Intervention and Industrial Research of Functional Probiotics in Metabolic Diseases,which drew a full house.
Dr. Xu emphasized that with evolving lifestyles, metabolic diseases such as hyperuricemia and diabetes have become major public health concerns impacting national well-being. Beyond traditional therapeutic approaches, nutritional interventions utilizing targeted functional probiotics present a promising auxiliary management strategy due to their safety and high compliance.
"The functional properties of probiotic strains are highly specific; not all probiotics possess identical regulatory capabilities. Our research focuses on screening strains with documented functional evidence at the source and ensuring their stable activity and efficacy through industrial-scale production processes," Dr. Xu explained. He systematically elaborated on Bioyitech's comprehensive R&D approach, encompassing strain screening, mechanistic studies, clinical validation, and industrial translation of functional probiotics.
Grand Launch: "Jiang Xiao Yi - Acid Series/Sugar Series" ProBiotic Powders Officially Unveiled
Leveraging the conference platform, Bioyitech officially introduced its clinically validated functional probiotic powders, the "Jiang Xiao Yi" series, developed with evidence from top-tier hospitals. This series features two specialized formulations tailored for distinct metabolic concerns:
Blood Glucose and Lipid Management/Probiotics Premix/ZC-SUGII: Specifically addresses uric acid metabolism. Its core strains have undergone in vitro functional evaluation and animal studies, and a clinical trial at the Guangdong Provincial People's Hospital has been completed. The results demonstrated positive effects in lowering serum uric acid levels, significantly reducing reliance on emergency gout medications, and decreasing the frequency and duration of gout attacks.
Uric Acid Reduction /Probiotics Premix/ZC-URA: Focuses on blood glucose homeostasis. Research on the selected strains has confirmed their positive role in improving insulin sensitivity and modulating gut microbiota composition. This formulation has undergone clinical evidence-based research at the Second Affiliated Hospital of Zhejiang University School of Medicine, providing robust scientific support for its efficacy.
The clinical validation of these two probiotic formulations by top-tier hospitals signifies a new era of more scientific, precise, and standardized development in the functional probiotic field.
Deep Integration of Industry, Academia, Research, and Medicine: Bioyitech Leads Industry Innovation
Throughout the conference, Bioyitech's booth attracted significant attention and engagement from attendees. Many clinicians, dietitians, and industry partners expressed strong interest in the Bioyitech strains series and engaged in in-depth discussions regarding the clinical applications and collaborative R&D of functional Probiotics.
《We firmly believe that future health products must be built upon solid scientific evidence. Clinical collaborations with leading top-tier hospitals not only validate product efficacy but, more importantly, provide trustworthy solutions for both healthcare professionals and consumers》Dr. Xu stated in a post-conference interview.
At this conference, Bioyitech not only showcased the R&D capabilities of Chinese enterprises in the functional probiotic sector but also fostered deep exchanges and collaborations across industry, academia, research, and medicine. With the launch of the "Jiang Xiao Yi" series, Bioyitech has taken a significant step forward in the industrialization of functional microorganisms, bringing new hope to individuals managing metabolic diseases.
Looking ahead, Bioyitech remains committed to the functional probiotic domain, aiming to develop more microecological intervention strategies for chronic diseases and contribute to the "Healthy China" initiative through technological innovation.
